Compare
Nektar Therapeutics vs Agios Pharmaceuticals, Inc. vs Aytu Biopharma, Inc vs Ocular Therapeutix, Inc
| Latest fiscal year | Nektar Therapeutics NKTR | Agios Pharmaceuticals, Inc. AGIO | Aytu Biopharma, Inc AYTU | Ocular Therapeutix, Inc OCUL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $55.23M | $54.03M | $57.57M | $51.95M |
| Revenue growth (YoY) | -43.9% | +48.0% | -13.3% | -18.5% |
| Gross margin | n/a | 88.3% (computed) | 64.0% | 87.3% (computed) |
| Operating margin | -253.7% | -873.9% | -14.4% | -519.8% |
| Net margin | -297.1% | -764.0% | -24.8% | -511.9% |
| Net income | -$164.08M | -$412.78M | -$14.25M | -$265.94M |
| EPS (Diluted) | -$9.73 | -$7.12 | n/a | -$1.42 |
| Operating cash flow | -$208.51M | -$372.98M | $3.28M | -$204.88M |
| Free cash flow | -$208.68M | -$377.29M | $3.25M | -$216.89M |
| Cash & equivalents | $15.12M | $89.13M | $26.31M | $737.06M |
| Total assets | $280.41M | $1.30B | $105.01M | $808.06M |
| Total liabilities | $190.57M | $104.11M | n/a | $153.75M |
| Shareholders' equity | $89.83M | $1.19B | $35.27M | $654.31M |
| Return on year-end equity | -182.6% | -34.6% | -40.4% | -40.6% |
| Shares outstanding | 20.38M | 58.45M | 10.73M | 215.93M |
Revenue, most recent five fiscal years
| Fiscal year | Nektar Therapeutics | Agios Pharmaceuticals, Inc. | Aytu Biopharma, Inc | Ocular Therapeutix, Inc |
|---|---|---|---|---|
| Latest | $55.23M Ended 2025-12-31 | $54.03M Ended 2025-12-31 | $57.57M Ended 2026-06-30 | $51.95M Ended 2025-12-31 |
| 1 year earlier | $98.43M Ended 2024-12-31 | $36.50M Ended 2024-12-31 | $66.38M Ended 2025-06-30 | $63.72M Ended 2024-12-31 |
| 2 years earlier | $90.12M Ended 2023-12-31 | $26.82M Ended 2023-12-31 | $65.18M Ended 2024-06-30 | $58.44M Ended 2023-12-31 |
| 3 years earlier | $92.06M Ended 2022-12-31 | $14.24M Ended 2022-12-31 | $107.40M Ended 2023-06-30 | $51.49M Ended 2022-12-31 |
| 4 years earlier | $101.91M Ended 2021-12-31 | $0 Ended 2021-12-31 | $96.67M Ended 2022-06-30 | $43.52M Ended 2021-12-31 |